Medtech insiders offer 10 strategies for medtech companies to rethink their businesses right now.
The COVID-19 pandemic has caused major disruption in people’s lives and driven many companies to rethink the way they conduct business. While no one can say with certainty what the pandemic will bring for medtech companies, Medtech Insight has consulted industry insiders to see how companies may quickly adapt to new unforeseen demands in the future and become better equipped to address challenges.
Here are 10 strategies for medtech companies to consider:
During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.
Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.
German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.
Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.
